India prostate cancer market is forecast to grow at a CAGR of around 9% during the forecast period. The incidence of prostate cancer is less as compared to the western economies as prostate cancer is among the top 3 cancer in men in western economies whereas it is at 16th rank in the incidence cancer cases in the country in 2018. As per the World Health Organization, the estimated new cases in 2018 were 26,000- and 5-year prevalence is around 47,500. In India, the registered cases of prostate cancer are more in big cities such as Bangalore, Mumbai, Pune, Kolkata, Delhi, and Thiruvananthapuram. The data for prostate cancer incidences in India is only indicative as there are no PSA testing norms in India at a mass scale which may result in many prostate cancer cases going unreported. In India, data regarding the true incidence of prostate cancer is limited mainly due to the fact that this entity is not a notifiable disease and there are only a handful of population-based cancer registries in India.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/indian-prostate-cancer-diagnostic-therapeutic-market
Moreover, the country’s age composition is that more than 50% of the population is below 25 years of age making it less demanding for prostate cancer services. This is due to the fact that the chances of having prostate cancer in men increase with increasing age. India has a population of 1.3 billion in 2020 and in 2020, the average age of an Indian is around 29 years compared to 37 years for a Chinese and 48 years for a Japanese. This makes it a less demanding market for prostate cancer services and diagnosis. However, the market will show impressive growth due to increasing medical tourism in the country. This is primarily due to cheaper healthcare services as compared to western economies.
The companies which are contributing significantly in the market include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Endo Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Siemens Healthcare AG, and others. The market players are considerably contributing to the market growth by the adoption of various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
A full report of India Prostate Cancer Diagnostic and Therapeutic Market available @ https://www.omrglobal.com/industry-reports/indian-prostate-cancer-diagnostic-therapeutic-market
India Prostate Cancer Market Segmentation
By Diagnostic Techniques
- Prostate-Specific Antigen Test (PSA)
- Digital Rectal Examination
- Prostate Biopsy
- Imaging Techniques
By Therapeutics
- Hormonal Therapy
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Targeted Therapy
- Surgery
Company Profiles
- Abbott Laboratories
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Co.
- Endo Pharmaceuticals Inc.
- Ferring Pharmaceuticals Inc.
- GlaxoSmithKline PLC
- Johnson & Johnson
- Pfizer Inc.
- Siemens Healthcare AG
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
